Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Prion-like disorders: blurring the divide between transmissibility and infectivity.

Cushman M, Johnson BS, King OD, Gitler AD, Shorter J.

J Cell Sci. 2010 Apr 15;123(Pt 8):1191-201. doi: 10.1242/jcs.051672.

2.

Amyloid-like interactions within nucleoporin FG hydrogels.

Ader C, Frey S, Maas W, Schmidt HB, Görlich D, Baldus M.

Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6281-5. doi: 10.1073/pnas.0910163107. Epub 2010 Mar 18.

3.

The glycosylphosphatidylinositol anchor is a major determinant of prion binding and replication.

Bate C, Tayebi M, Williams A.

Biochem J. 2010 Apr 28;428(1):95-101. doi: 10.1042/BJ20091469.

PMID:
20196773
4.

Interaction with AKAP79 modifies the cellular pharmacology of PKC.

Hoshi N, Langeberg LK, Gould CM, Newton AC, Scott JD.

Mol Cell. 2010 Feb 26;37(4):541-50. doi: 10.1016/j.molcel.2010.01.014.

5.

Exploring the sequence determinants of amyloid structure using position-specific scoring matrices.

Maurer-Stroh S, Debulpaep M, Kuemmerer N, Lopez de la Paz M, Martins IC, Reumers J, Morris KL, Copland A, Serpell L, Serrano L, Schymkowitz JW, Rousseau F.

Nat Methods. 2010 Mar;7(3):237-42. doi: 10.1038/nmeth.1432. Epub 2010 Feb 14.

PMID:
20154676
6.

Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation.

Si K, Choi YB, White-Grindley E, Majumdar A, Kandel ER.

Cell. 2010 Feb 5;140(3):421-35. doi: 10.1016/j.cell.2010.01.008.

7.

Applying Hsp104 to protein-misfolding disorders.

Vashist S, Cushman M, Shorter J.

Biochem Cell Biol. 2010 Feb;88(1):1-13. doi: 10.1139/o09-121. Review.

8.

Generating a prion with bacterially expressed recombinant prion protein.

Wang F, Wang X, Yuan CG, Ma J.

Science. 2010 Feb 26;327(5969):1132-5. doi: 10.1126/science.1183748. Epub 2010 Jan 28.

9.

Protease-sensitive synthetic prions.

Colby DW, Wain R, Baskakov IV, Legname G, Palmer CG, Nguyen HO, Lemus A, Cohen FE, DeArmond SJ, Prusiner SB.

PLoS Pathog. 2010 Jan 22;6(1):e1000736. doi: 10.1371/journal.ppat.1000736.

10.

Mutational robustness can facilitate adaptation.

Draghi JA, Parsons TL, Wagner GP, Plotkin JB.

Nature. 2010 Jan 21;463(7279):353-5. doi: 10.1038/nature08694.

11.

Differences in prion strain conformations result from non-native interactions in a nucleus.

Ohhashi Y, Ito K, Toyama BH, Weissman JS, Tanaka M.

Nat Chem Biol. 2010 Mar;6(3):225-230. Epub 2010 Jan 17.

12.

Prions, protein homeostasis, and phenotypic diversity.

Halfmann R, Alberti S, Lindquist S.

Trends Cell Biol. 2010 Mar;20(3):125-33. doi: 10.1016/j.tcb.2009.12.003. Epub 2010 Jan 12.

13.

The transcellular spread of cytosolic amyloids, prions, and prionoids.

Aguzzi A, Rajendran L.

Neuron. 2009 Dec 24;64(6):783-90. doi: 10.1016/j.neuron.2009.12.016. Review.

14.

GPI anchoring facilitates propagation and spread of misfolded Sup35 aggregates in mammalian cells.

Speare JO, Offerdahl DK, Hasenkrug A, Carmody AB, Baron GS.

EMBO J. 2010 Feb 17;29(4):782-94. doi: 10.1038/emboj.2009.392. Epub 2010 Jan 7.

15.

Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models.

Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, Strathearn KE, Liu F, Cao S, Hamamichi S, Hill KJ, Caldwell KA, Bell GW, Fraenkel E, Cooper AA, Caldwell GA, McCaffery JM, Rochet JC, Lindquist S.

Dis Model Mech. 2010 Mar-Apr;3(3-4):194-208. doi: 10.1242/dmm.004267. Epub 2009 Dec 28.

16.

Discovery of 2-aminothiazoles as potent antiprion compounds.

Ghaemmaghami S, May BC, Renslo AR, Prusiner SB.

J Virol. 2010 Apr;84(7):3408-12. doi: 10.1128/JVI.02145-09. Epub 2009 Dec 23.

17.

Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines.

Bate C, Tayebi M, Diomede L, Salmona M, Williams A.

PLoS One. 2009 Dec 9;4(12):e8221. doi: 10.1371/journal.pone.0008221.

18.

Reduced IGF-1 signaling delays age-associated proteotoxicity in mice.

Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A, Pham HM, Holzenberger M, Kelly JW, Masliah E, Dillin A.

Cell. 2009 Dec 11;139(6):1157-69. doi: 10.1016/j.cell.2009.11.014.

19.

Continuous quinacrine treatment results in the formation of drug-resistant prions.

Ghaemmaghami S, Ahn M, Lessard P, Giles K, Legname G, DeArmond SJ, Prusiner SB.

PLoS Pathog. 2009 Nov;5(11):e1000673. doi: 10.1371/journal.ppat.1000673. Epub 2009 Nov 26.

20.

The spontaneous appearance rate of the yeast prion [PSI+] and its implications for the evolution of the evolvability properties of the [PSI+] system.

Lancaster AK, Bardill JP, True HL, Masel J.

Genetics. 2010 Feb;184(2):393-400. doi: 10.1534/genetics.109.110213. Epub 2009 Nov 16.

Supplemental Content

Support Center